Details: pack, label wording, sources, registration
Optovit B12 1000 mcg/2 ml, Solution
2 ml ampoule, solution for injection, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
SC or IM cyanocobalamin replacement for documented or strongly supported cobalamin deficiency when parenteral treatment is clinically preferred; not nonspecific appetite support, a tonic or automatic treatment of every gastrointestinal disorder
7.1/10
Good
Details →
vetman assessment
Optovit B12
×
1000 mcg/2 ml, 2 ml ampoule, solution for injection, human medicine
Assessed clinical scope Dog · SC or IM cyanocobalamin replacement for documented or strongly supported cobalamin deficiency when parenteral treatment is clinically preferred; not nonspecific appetite support, a tonic or automatic treatment of every gastrointestinal disorder · SC,IM
Care setting Veterinary clinic or a trained home-treatment plan after deficiency and cause assessment, with exact small-volume measurement, injection-site rotation, follow-up cobalamin or methylmalonic-acid testing and treatment of the underlying disease
vetman score
7.1/10
Good
Evidence confidence: Medium
Georgia: Yes, human · № რ-044999 · Verified on 16 Oct 2026
Off-label use
A useful, generally safe parenteral replacement when true cobalamin deficiency is documented or strongly supported and injection is preferred for severity, adherence or clinical context. It should accompany cause-directed care and follow-up testing; oral supplementation is a credible less-invasive alternative for many stable dogs and cats.
Regulatory and scientific credibility 5.5/10
The exact human cyanocobalamin ampoule has a sourced current Georgian registration and identifiable strength, route and manufacturer, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary use is off-label and exact-product animal evidence is absent.
Clinical efficacy 7.5/10
Parenteral cobalamin reliably raises cobalamin and lowers methylmalonic acid in deficient dogs and cats, with feline clinical improvement reported and randomized canine evidence supporting biochemical normalization. It remains adjunctive to diagnosis and treatment of enteropathy, exocrine pancreatic insufficiency or another cause; oral cobalamin is often similarly effective, so injections are not inherently superior for every stable patient.
Safety and tolerability 8.0/10
Cyanocobalamin has a wide therapeutic margin and serious toxicity is uncommon. Relevant risks are injection pain, local inflammation, rare cobalt/cobalamin or excipient hypersensitivity including anaphylaxis, and potassium decline during brisk correction of severe deficiency; the exact human ampoule excipients and neonatal suitability require verification.
Clinical practicality 7.5/10
The sterile 500 mcg/ml single-use ampoule is straightforward for SC or IM replacement; a 250 mcg feline dose is 0.5 ml and published canine weight-band amounts fit practical volumes. Repeated injections and visits remain a burden compared with effective daily oral supplementation, and the ampoule remainder must be discarded.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not administer to a patient with known cobalt, cobalamin or product-excipient hypersensitivity. Parenteral vitamin B12 has rarely caused anaphylaxis; have observation and emergency treatment available, especially after a previous unexplained injection reaction. Confirm deficiency with an appropriate cobalamin assay and, when results or clinical response are equivocal, methylmalonic acid or other diagnostic context. Do not use cyanocobalamin as an empirical tonic, nonspecific appetite stimulant or substitute for investigating weight loss, anaemia, neuropathy or chronic gastrointestinal signs. Treat the cause of deficiency, including chronic enteropathy, ileal disease, exocrine pancreatic insufficiency, altered intestinal anatomy or an inadequate diet. Cobalamin can correct a deficiency marker but cannot by itself control inflammation, infection, pancreatic failure, neoplasia or malnutrition. Recheck clinical response and serum cobalamin after the replacement course and consider methylmalonic acid when functional deficiency remains uncertain. Draw planned baseline samples before supplementation and interpret very high post-treatment concentrations in light of timing rather than escalating automatically. During brisk correction of severe deficiency or megaloblastic anaemia, monitor potassium and the haematologic response; hypokalaemia and arrhythmia have been reported with intensive parenteral replacement. Investigate concurrent folate, iron or other deficiencies rather than assuming nonresponse means a higher B12 dose. Oral cobalamin normalized biochemical markers similarly to injections in randomized canine studies and has supportive feline evidence. Reassess whether repeated SC/IM visits, restraint and injection discomfort add value for a stable patient who can reliably receive an appropriate oral product. Verify the exact ampoule excipients before neonatal, very small, renal-impaired or repeated use; human cyanocobalamin products may contain benzyl alcohol or trace aluminum, and formulations are not interchangeable by appearance. Use only the labelled SC/IM routes and concentration. Protect the ampoule from light according to its insert, inspect the solution and container, use an accurate low-dead-space syringe and aseptic technique, rotate injection sites, and discard the unused remainder of a breached single-use ampoule rather than sharing it between patients. Assessment sources +
Close
Cat
SC or IM cyanocobalamin replacement for documented or strongly supported cobalamin deficiency when parenteral treatment is clinically preferred; not nonspecific appetite support, a tonic or automatic treatment of every gastrointestinal disorder
7.1/10
Good
Details →
vetman assessment
Optovit B12
×
1000 mcg/2 ml, 2 ml ampoule, solution for injection, human medicine
Assessed clinical scope Cat · SC or IM cyanocobalamin replacement for documented or strongly supported cobalamin deficiency when parenteral treatment is clinically preferred; not nonspecific appetite support, a tonic or automatic treatment of every gastrointestinal disorder · SC,IM
Care setting Veterinary clinic or a trained home-treatment plan after deficiency and cause assessment, with exact small-volume measurement, injection-site rotation, follow-up cobalamin or methylmalonic-acid testing and treatment of the underlying disease
vetman score
7.1/10
Good
Evidence confidence: Medium
Georgia: Yes, human · № რ-044999 · Verified on 16 Oct 2026
Off-label use
A useful, generally safe parenteral replacement when true cobalamin deficiency is documented or strongly supported and injection is preferred for severity, adherence or clinical context. It should accompany cause-directed care and follow-up testing; oral supplementation is a credible less-invasive alternative for many stable dogs and cats.
Regulatory and scientific credibility 5.5/10
The exact human cyanocobalamin ampoule has a sourced current Georgian registration and identifiable strength, route and manufacturer, while exhaustive current checks record it as not registered in EU/EEA, GB or US. Veterinary use is off-label and exact-product animal evidence is absent.
Clinical efficacy 7.5/10
Parenteral cobalamin reliably raises cobalamin and lowers methylmalonic acid in deficient dogs and cats, with feline clinical improvement reported and randomized canine evidence supporting biochemical normalization. It remains adjunctive to diagnosis and treatment of enteropathy, exocrine pancreatic insufficiency or another cause; oral cobalamin is often similarly effective, so injections are not inherently superior for every stable patient.
Safety and tolerability 8.0/10
Cyanocobalamin has a wide therapeutic margin and serious toxicity is uncommon. Relevant risks are injection pain, local inflammation, rare cobalt/cobalamin or excipient hypersensitivity including anaphylaxis, and potassium decline during brisk correction of severe deficiency; the exact human ampoule excipients and neonatal suitability require verification.
Clinical practicality 7.5/10
The sterile 500 mcg/ml single-use ampoule is straightforward for SC or IM replacement; a 250 mcg feline dose is 0.5 ml and published canine weight-band amounts fit practical volumes. Repeated injections and visits remain a burden compared with effective daily oral supplementation, and the ampoule remainder must be discarded.
Full-course cost-effectiveness -
Price was not assessed and is excluded from the overall score.
Important safety and use flags
Do not administer to a patient with known cobalt, cobalamin or product-excipient hypersensitivity. Parenteral vitamin B12 has rarely caused anaphylaxis; have observation and emergency treatment available, especially after a previous unexplained injection reaction. Confirm deficiency with an appropriate cobalamin assay and, when results or clinical response are equivocal, methylmalonic acid or other diagnostic context. Do not use cyanocobalamin as an empirical tonic, nonspecific appetite stimulant or substitute for investigating weight loss, anaemia, neuropathy or chronic gastrointestinal signs. Treat the cause of deficiency, including chronic enteropathy, ileal disease, exocrine pancreatic insufficiency, altered intestinal anatomy or an inadequate diet. Cobalamin can correct a deficiency marker but cannot by itself control inflammation, infection, pancreatic failure, neoplasia or malnutrition. Recheck clinical response and serum cobalamin after the replacement course and consider methylmalonic acid when functional deficiency remains uncertain. Draw planned baseline samples before supplementation and interpret very high post-treatment concentrations in light of timing rather than escalating automatically. During brisk correction of severe deficiency or megaloblastic anaemia, monitor potassium and the haematologic response; hypokalaemia and arrhythmia have been reported with intensive parenteral replacement. Investigate concurrent folate, iron or other deficiencies rather than assuming nonresponse means a higher B12 dose. Oral cobalamin normalized biochemical markers similarly to injections in randomized canine studies and has supportive feline evidence. Reassess whether repeated SC/IM visits, restraint and injection discomfort add value for a stable patient who can reliably receive an appropriate oral product. Verify the exact ampoule excipients before neonatal, very small, renal-impaired or repeated use; human cyanocobalamin products may contain benzyl alcohol or trace aluminum, and formulations are not interchangeable by appearance. Use only the labelled SC/IM routes and concentration. Protect the ampoule from light according to its insert, inspect the solution and container, use an accurate low-dead-space syringe and aseptic technique, rotate injection sites, and discard the unused remainder of a breached single-use ampoule rather than sharing it between patients. Assessment sources +
Close
Administration route
Subcutaneous, Intramuscular
Registration
Georgia
Yes, human
In force until 16 Mar 2031
Human (Ministry of Health, RAMA)
In the register: ოპტოვიტი B12 1000 მკგ/2 მლ, 2 მლ ამპულა, საინექციო ხსნარი
№ რ-044999
Verified on: 16 Oct 2026
EU
No
UK
No
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
